glp-1 agonists for obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH GLP1 Receptor Agonists—Effects beyond Obesity

Melo AS, Ferriani RA, Navarro PA

Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial

SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia

Notably, metabolic benefits often diminish after treatment discontinuation [116], underscoring the importance of long-term planning in therapeutic decision-making

But GLP-1 medications do much more than blunt appetite

No long waits, inflated prices or unanswered questions just real, accessible care from anywhere